ACADIA Pharmaceuticals Inc. (ACAD)’s Financial Results Comparing With Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

As Biotechnology companies, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) are our subject to compare. And more specifically their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ACADIA Pharmaceuticals Inc. 207.80M 15.36 248.57M -1.44 0.00
Oramed Pharmaceuticals Inc. 2.51M 22.69 14.50M -0.86 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 shows us the return on assets, return on equity and net margins of both companies.

Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals Inc. -119.62% -88.2% -75.5%
Oramed Pharmaceuticals Inc. -577.69% -55.9% -31.5%

Volatility and Risk

ACADIA Pharmaceuticals Inc. has a 3.32 beta, while its volatility is 232.00% which is more volatile than S&P 500. Oramed Pharmaceuticals Inc.’s 81.00% less volatile than S&P 500 which is a result of the 0.19 beta.


ACADIA Pharmaceuticals Inc.’s Current Ratio is 6.1 while its Quick Ratio is 6. On the competitive side is, Oramed Pharmaceuticals Inc. which has a 6.8 Current Ratio and a 6.8 Quick Ratio. Oramed Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to ACADIA Pharmaceuticals Inc.

Analyst Recommendations

The Ratings and Recommendations for ACADIA Pharmaceuticals Inc. and Oramed Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ACADIA Pharmaceuticals Inc. 0 3 3 2.50
Oramed Pharmaceuticals Inc. 0 0 0 0.00

$27.17 is ACADIA Pharmaceuticals Inc.’s average price target while its potential upside is 22.22%.

Insider & Institutional Ownership

ACADIA Pharmaceuticals Inc. and Oramed Pharmaceuticals Inc. has shares owned by institutional investors as follows: 86.7% and 23.4%. Insiders owned roughly 0.1% of ACADIA Pharmaceuticals Inc.’s shares. Competitively, 5.6% are Oramed Pharmaceuticals Inc.’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ACADIA Pharmaceuticals Inc. -1.47% -6.1% 34.62% 5.09% -37.59% -37.63%
Oramed Pharmaceuticals Inc. 0% -3.41% -18.73% -45.67% -53.74% -54.67%

For the past year ACADIA Pharmaceuticals Inc. was less bearish than Oramed Pharmaceuticals Inc.


Oramed Pharmaceuticals Inc. beats on 6 of the 11 factors ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.